Sarepta Therapeutics | Biopharmaceutical Company for Rare …
WEBSarepta is engineering solutions for rare diseases with science that is on the forefront of precision genetic medicine. Our platforms include: gene therapy, RNA technologies, and gene editing. We are in a daily race to save lives stolen or impacted by rare disease.
Sarepta Therapeutics, Inc. (SRPT) - Yahoo Finance
WEBSarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic...
Muscular dystrophy patients get first gene therapy - NPR
WEBJun 22, 2023 · Sarepta's muscular dystrophy treatment is the first gene therapy approved under the program. The disease, which almost exclusively affects boys, destroys muscles.
News & Press Releases | Sarepta Therapeutics
WEBRead news and articles from Sarepta, a global biotechnology company developing potentially life-changing precision genetic medicine.
Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the …
WEBJun 22, 2023 · Sarepta Therapeutics Announces FDA Approval of ELEVIDYS, the First Gene Therapy to Treat Duchenne Muscular Dystrophy. 06/22/23 2:02 PM EDT. ELEVIDYS (delandistrogene moxeparvovec-rokl) is approved for the treatment of ambulatory pediatric patients aged 4 through 5 years with Duchenne based on expression of ELEVIDYS …
About Our Company | Sarepta Therapeutics
WEBSarepta is a global biotechnology company on an urgent mission: to engineer precision genetic medicine for rare diseases that devastate lives and cut futures short.
Sarepta Therapeutics Announces Expanded US FDA Approval of …
WEBJun 20, 2024 · Sarepta is on an urgent mission: engineer precision genetic medicine for rare diseases that devastate lives and cut futures short. We hold leadership positions in Duchenne muscular dystrophy (DMD) and limb-girdle muscular dystrophies (LGMDs), and we currently have more than 40 programs in various stages of development.
Sarepta Therapeutics Announces U.S. FDA Acceptance of an …
WEBFeb 16, 2024 · CAMBRIDGE, Mass. -- (BUSINESS WIRE)--Feb. 16, 2024-- Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced the U.S. Food and Drug Administration (FDA) has accepted and filed the Company's efficacy supplement to the Biologics License Application (BLA) for …
SRPT Stock Price | Sarepta Therapeutics Inc. Stock Quote (U.S.: …
WEB3 days ago · Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases.
Sarepta Therapeutics - Wikipedia
WEBSarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States.
Skip to content